Please login to the form below

Not currently logged in
Email:
Password:

Sanofi launches bursary scheme in UK

Funding to support initiatives that promote patient empowerment and education
Sanofi reception

Sanofi has launched its 2014 bursary scheme to support patient groups in the UK.

A total of £50,000 will be shared between three groups working to promote patient empowerment and education.

Of this fund, the winner of the Gold grant will receive £25,000 and the Silver grant will receive £15,000.

The 2014 initiative is also the first time that Sanofi has introduced a separate category for small organisations with an annual income of £300,000 or less.

The successful applicant in this group will win £10,000 to support its work.

“It is a privilege for Sanofi UK to continue the Patient Group Bursary Scheme into its fourth year,” said Steve Oldfield, managing director of Sanofi UK and Ireland. “Since 2011, we have seen winners of the scheme make a huge difference to the lives of patients and their families and carers.”

This was backed by winner of the 2013 Gold bursary, Lynne Regent, CEO of Anaphylaxis Campaign.

“The Sanofi Patient Group Bursary Scheme has enabled the Anaphylaxis Campaign to broaden our support for parents with children who are affected by severe food allergies.

“Specialist training programmes for our ten new support group volunteers means we can now provide high quality peer-to-peer support for other families dealing with the consequences of life-threatening allergies.”

Patient groups have until May 28 to apply for a bursary. Application forms are available on Sanofi's UK website.

Article by
Thomas Meek

25th April 2014

From: Marketing, Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics